18 results
8-K
MIRA
Mira Pharmaceuticals Inc
12 Jul 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
believes will support the Company’s efforts to achieve both near and long-term shareholder value growth and regain compliance with the Minimum Bid
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
economic and commercial rights to our programs in key geographic areas that are core to our long-term strategy.
Competition
Ketamir-2
The principle … regulator, BRD4’s role in modifying the expression of genes without changing the DNA sequence might be crucial in understanding the long-term impact
8-K
EX-1.1
MIRA
Mira Pharmaceuticals Inc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
of business, any grants under any stock compensation plan, and (d) there has not been any Material Adverse Change in the Company’s long-term or short
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
improvement as a direct effect on the brain that is independent of indirect effects—such as with acute administration by decreasing anxiety or with long term administration … revenues will be limited, which would have a material adverse impact on our long-term business, results of operations, financial condition, and prospects
424B1
otf92 j3zrom
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
EX-99.2
y61x33tfahr1yo
29 Jun 23
IPO registration
4:39pm
S-1
EX-99.4
9uue 9gi3l6s
29 Jun 23
IPO registration
4:39pm
S-1
fy4tchqiqj6yt9
29 Jun 23
IPO registration
4:39pm
S-1
EX-10.1
rs16u2u2jh8n1ffsmnxc
29 Jun 23
IPO registration
4:39pm
DRS/A
EX-99.2
hnfdladk084ojqiejz
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
5er9 o49i7o
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
rfblfpav1vqkskw
2 May 23
Draft registration statement (amended)
12:00am
DRS
ksbngde17 65bn3e
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next